Laurus Labs Ltd (LAURUSLABS) Q2FY27 Concall Summary - Sep-2026 Qtr
Key Takeaways
- The company will acquire a 60% stake in Canada-based Galenvs Sciences to enter the high-growth oligonucleotide CDMO market where it currently has no presence.
- A new commercial-scale peptide facility with over 16,000L capacity has been commissioned, with significant further expansions planned due to strong program visibility.
- Management reaffirmed guidance for sustained EBITDA margins above 30% and gross margins over 60%, signaling confidence despite a record high margin of 34.5% in Q2.
Performance Overview
- Laurus Labs reported record-breaking revenue and profits in Q2 FY27, driven by strong growth in the CDMO business and steady performance in affordable medicines.
- The company's transformation strategy is advancing with significant investments in new capabilities, including the commissioning of a commercial-scale peptide manufacturing block.
- Strategic acquisitions were announced to bolster capabilities in high-growth areas: a 60% stake in Galenvs Sciences for oligonucleotides and a majority stake in Seanc Resins for peptide synthesis raw materials.
- The CDMO segment demonstrated robust growth, supported by the delivery of late-stage programs and commercial API supplies to global partners.
- The company maintained healthy profitability, with EBITDA margins expanding to 34.5% due to a favorable product mix and improved operational leverage.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.
Tone & Disclosure
Log in to Stocksigma to read the Tone & Disclosure section of this summary.